McKesson Corporation
MCK
$858.90
+2.40%
McKesson Corporation is a leading pharmaceutical wholesaler and healthcare services company, distributing branded, generic, and specialty pharmaceuticals to pharmacies, hospitals, and healthcare providers across the U.S. and Canada, while also offering medical-surgical supplies and pharmacy technology solutions. As one of the 'Big Three' wholesalers alongside Cencora and Cardinal Health, McKesson commands over 90% of the U.S. pharmaceutical wholesale market, positioning it as a critical intermediary in the healthcare supply chain. The current investor narrative centers on the company's ability to sustain growth through its oncology and specialty segments, expand margins via technology and value-added services, and navigate the ongoing opioid litigation overhang, with recent quarterly results showing robust revenue growth and strong free cash flow generation.…
MCK
McKesson Corporation
$858.90
Investment Opinion: Should I buy MCK Today?
Based on the analysis, MCK is rated a Buy. The stock offers a compelling risk/reward with a forward PE of 16.99x, a PEG ratio of 0.46, and an average analyst target of $986.94, implying ~14.9% upside. The company's dominant market position, robust revenue growth (6.02% YoY in Q4), and strong free cash flow ($5.94B) support the thesis. The low beta (0.307) provides defensive characteristics, making it suitable for conservative investors seeking growth at a reasonable price.
Sign up to view all
MCK 12-Month Price Forecast
The AI assessment leans bullish due to McKesson's attractive valuation, solid growth, and defensive characteristics. The forward PE is at a discount to peers, and the PEG ratio suggests the stock is undervalued relative to its growth rate. However, the medium confidence reflects the overhang of opioid litigation and the thin margins. If the company can sustain its growth and manage legal costs, the stock has significant upside potential. Key developments to watch include quarterly earnings, opioid settlement news, and margin trends. An upgrade to high confidence would occur if the company reports accelerating revenue growth and expanding margins, while a downgrade would follow if legal costs escalate or margins deteriorate.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on McKesson Corporation's 12-month outlook, with a consensus price target around $986.94 and implied upside of +14.9% versus the current price.
Average Target
$986.94
0 analysts
Implied Upside
+14.9%
vs. current price
Analyst Count
—
covering this stock
Price Range
$845 - $1080
Analyst target range
The target price range spans from $845 (low) to $1,080 (high), representing a spread of 27.8% from low to high, indicating moderate uncertainty. The low target of $845 is slightly below the current price, suggesting some analysts see downside risk, possibly due to opioid litigation costs or margin compression. The high target of $1,080 implies a 25.7% upside, likely assuming continued strength in specialty pharmaceuticals and successful execution of technology initiatives. Recent institutional ratings have been stable, with no downgrades in the past six months, reinforcing a positive outlook. The wide range reflects the balance between the company's strong cash flow and growth potential against regulatory and legal overhangs.
Bulls vs Bears: MCK Investment Factors
McKesson presents a mixed picture: strong revenue growth, robust cash flow, and an attractive valuation on forward earnings are countered by thin margins, opioid litigation overhang, and a leveraged balance sheet. The bull case is supported by the company's dominant market position and strategic shift to higher-margin specialty and technology services, while the bear case hinges on legal liabilities and margin vulnerability. Currently, the evidence slightly favors the bull side, given the PEG ratio of 0.46 and analyst consensus Buy, but the key tension is whether the company can sustain its growth and margin expansion while managing legal costs. The resolution of opioid litigation and the success of oncology/technology initiatives will be pivotal in determining the stock's trajectory.
Bullish
- Strong Revenue Growth: Q4 FY2026 revenue grew 6.02% YoY to $96.3B, with full-year revenue reaching $403.4B, up from $380.8B in FY2025. This growth is driven by the North American Pharmaceutical segment, which contributes $161.8B annually, and the expanding Oncology and Multispecialty segment ($23.4B).
- Undervalued on Forward PE: The forward PE of 16.99x is at a discount to the trailing PE of 22.45x and the industry average of 22.5x, implying the market expects ~32% EPS growth. The PEG ratio of 0.46 suggests the stock is undervalued relative to its growth rate, making it an attractive GARP candidate.
- Robust Free Cash Flow: TTM free cash flow stands at $5.94B, providing ample capacity for debt reduction, share buybacks, and strategic investments. This strong cash generation supports the company's ability to navigate legal liabilities and fund growth initiatives.
- Analyst Consensus Buy: With a mean recommendation of 1.61 (Buy) and an average target price of $986.94, analysts see ~14.9% upside from the current price of $858.90. The high target of $1,080 implies a 25.7% upside, reflecting confidence in the company's growth trajectory.
Bearish
- Opioid Litigation Overhang: The company faces ongoing opioid-related lawsuits and settlement costs, which have historically weighed on earnings and created uncertainty. The low analyst target of $845 is below the current price, suggesting some analysts see downside risk from these legal liabilities.
- Thin Gross Margins: Gross margin is only 3.6% (TTM), reflecting the low-margin nature of pharmaceutical distribution. This leaves little room for error, as any cost inflation or pricing pressure could significantly impact profitability.
- Negative Equity and High Debt: The debt-to-equity ratio is -3.97x, indicating negative shareholders' equity, likely due to share buybacks and acquisitions. This financial structure increases risk, as the company relies on debt financing and has limited equity buffer.
- Recent Price Volatility: The stock experienced a max drawdown of -27.17% from its 52-week high of $999.00 to the low of $673.38, and is still ~14% below that high. This volatility, partly driven by market sentiment and legal news, could persist.
MCK Technical Analysis
McKesson's stock has demonstrated a strong long-term uptrend, with a 1-year price change of +21.66%, significantly outperforming the S&P 500's +20.48% over the same period. The current price of $858.90 sits at approximately 86% of the 52-week range (low $673.38, high $999.00), indicating the stock is trading in the upper-middle portion of its range, reflecting a recovery from the May 2026 selloff but still below its February 2026 highs. This positioning suggests a constructive but not overextended trend, with room for upside if momentum continues.
Beta
0.31
0.31x market volatility
Max Drawdown
-27.2%
Largest decline past year
52-Week Range
$673-$999
Price range past year
Annual Return
+21.7%
Cumulative gain past year
| Period | MCK Return | S&P 500 |
|---|---|---|
| 1m | +5.5% | +3.6% |
| 3m | +12.1% | +2.7% |
| 6m | -9.3% | +11.4% |
| 1y | +21.7% | +18.7% |
| ytd | +4.3% | +12.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
MCK Fundamental Analysis
McKesson's revenue trajectory remains robust, with the most recent quarter (Q4 FY2026, ended March 31, 2026) reporting $96.3 billion in revenue, a 6.02% year-over-year increase. Over the past four quarters, revenue has grown from $97.8 billion (Q1) to $106.2 billion (Q3) and then to $96.3 billion (Q4), reflecting a seasonal pattern but with a solid underlying growth rate. The North American Pharmaceutical segment, contributing $161.8 billion annually, remains the primary growth driver, while the Oncology and Multispecialty segment ($23.4 billion) and Prescription Technology Solutions ($2.9 billion) are expanding, indicating a strategic shift toward higher-margin specialty and technology services.
Quarterly Revenue
$96.3B
2026-03
Revenue YoY Growth
+6.0%
YoY Comparison
Gross Margin
4.2%
Latest Quarter
Free Cash Flow
$5.9B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is MCK Overvalued?
Given McKesson's positive net income, the price-to-earnings (PE) ratio is the primary valuation metric. The trailing PE stands at 22.45x, while the forward PE is 16.99x, implying the market expects significant earnings growth (approximately 32% EPS growth) over the next year. This gap is supported by the company's PEG ratio of 0.46, suggesting the stock is undervalued relative to its growth rate. Compared to the industry average PE of 22.5x (based on available data), McKesson's trailing PE is roughly in line, but its forward PE is at a discount, indicating the market is pricing in above-average growth expectations.
PE
22.4x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 12x~31x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
15.5x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: McKesson's balance sheet shows negative equity (debt-to-equity of -3.97x), indicating that liabilities exceed assets, a result of aggressive share buybacks and acquisitions. This leverage increases financial risk, especially if interest rates rise or cash flows decline. The company's gross margin is razor-thin at 3.6%, leaving little buffer for cost increases or pricing pressure from customers. Additionally, revenue is concentrated in the low-margin distribution segment, with the North American Pharmaceutical segment contributing $161.8B annually, making the company sensitive to any disruption in that market. Free cash flow of $5.94B is strong, but a significant portion may be needed for debt servicing and legal settlements, limiting flexibility.
FAQ
The key risks for MCK include: 1) Opioid litigation: The company faces ongoing lawsuits and settlement costs, which could be substantial and unpredictable. 2) Margin compression: With a gross margin of only 3.6%, any increase in costs or pricing pressure from customers could significantly impact profitability. 3) Regulatory changes: Changes in drug pricing regulations or distribution requirements could affect the business model. 4) Financial leverage: The company has negative equity (debt-to-equity of -3.97x), indicating high leverage, which increases financial risk. These risks are ranked by severity, with opioid litigation being the most significant due to its potential magnitude and uncertainty.
The 12-month forecast for MCK is positive, with a base case target of $986.94 (analyst average) and a bull case target of $1,080 (analyst high). The bear case target is $845 (analyst low), but the probability of that scenario is lower at 20%. The most likely scenario (50% probability) is the base case, where the stock trades around $986.94, implying ~14.9% upside. The bull case (30% probability) could see the stock reach $1,080 if the company executes well on growth initiatives and resolves legal issues favorably. The bear case (20% probability) could see the stock decline to $845 if legal costs escalate or margins deteriorate. Overall, the forecast is bullish, with a favorable risk/reward.
Based on valuation metrics, MCK is undervalued. The trailing PE of 22.45x is in line with the industry average of 22.5x, but the forward PE of 16.99x is at a discount, implying the market expects strong earnings growth. The PEG ratio of 0.46 is well below 1, indicating that the stock is trading at a discount to its growth rate. Additionally, the price-to-sales ratio of 0.27 is low, reflecting the low-margin nature of the business. The market appears to be pricing in the risks of opioid litigation and thin margins, but the growth prospects in specialty and technology are not fully reflected. Overall, the stock is undervalued relative to its growth potential.
Yes, MCK appears to be a good buy for investors with a medium-to-long-term horizon. The stock trades at a forward PE of 16.99x, which is below the industry average of 22.5x, and has a PEG ratio of 0.46, indicating it is undervalued relative to its growth rate. Analyst consensus is a Buy with an average target price of $986.94, implying ~14.9% upside. The main risk is the opioid litigation overhang, which could lead to significant costs, but the company's strong cash flow and dominant market position provide a cushion. For investors comfortable with this risk, MCK offers a compelling risk/reward.
MCK is more suitable for long-term investment due to its defensive characteristics and growth potential. The stock has a beta of 0.307, indicating low volatility, and pays a small dividend (yield 0.36%). The company's earnings visibility is supported by its dominant market position and long-term contracts, making it a stable holding. Short-term trading could be challenging due to the stock's sensitivity to legal news and market sentiment, but long-term investors can benefit from the company's growth in specialty and technology segments. A suggested minimum holding period is 3-5 years to allow the growth initiatives to materialize and legal overhangs to resolve.